Intercell receives "The Vaccine Industry Excellence Award"

» Intercell's Hepatitis C vaccine candidate was awarded in the
category
of "Best New Therapeutic Vaccine" at the World Vaccine
Congress

» Intercell's therapeutic Hepatitis C vaccine
successfully concluded
Phase II clinical trials in February 2008

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

companies

Wien (euro adhoc) - Vienna (Austria), April 24, 2008 - In the course
of the World Vaccine Congress in Washington D.C., USA, Intercell was
awarded "The Vaccine Industry Excellence Award" in the category "Best
New Therapeutic Vaccine" for its therapeutic Hepatitis C (HCV)
vaccine candidate.

Earlier this year, Intercell's therapeutic vaccine candidate against
HCV successfully concluded Phase II clinical trials. The novel
vaccine is designed to stimulate T-cell responses against viral
protein structures conserved throughout the major HCV genotypes in
order to reduce viral load in the blood of chronically infected
patients.

"We are pleased to receive this award for our novel therapeutic
Hepatitis C vaccine. The latest Phase II data provides a strong base
to further strengthen our Hepatitis C franchise and to accelerate our
efforts towards a most valuable potential component in a combination
treatment for HCV," stated Alexander von Gabain, Chief Scientific
Officer of Intercell.

To improve and accelerate the development of a therapeutic Hepatitis
C vaccine, Intercell and its partner Novartis will take advantage of
an enlarged antigen portfolio and of IC31®, Intercell´s
second-generation adjuvant.

With representatives from over 200 individual companies, the "World
Vaccine Congress", taking place in Washington D.C. (USA) from April
21-24, 2008, is one of the largest and most important vaccine
industry meetings this year.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Communications

Tel. +43 1 20620-303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market